Neuronetics Q1 revenue rises 8%, slightly beats estimates

Overview

• U.S. neurohealth device maker's Q1 revenue rose 8%, slightly beating analyst expectations

• Net loss per share narrowed to $0.16 from $0.21 a year earlier

• Gross margin declined to 46.9% from 49.2%, mainly due to product mix

Outlook

• Neuronetics expects Q2 2026 revenue growth in the mid-single digits

• Company maintains 2026 revenue guidance of $160 mln to $166 mln

• Neuronetics sees 2026 gross margin between 47% and 49%

Result Drivers

• U.S. CLINIC GROWTH - Higher U.S. clinic revenue, up 15% year-over-year, driven by Greenbrook acquisition and SPRAVATO expansion, including buy and bill model

• SYSTEM SALES - U.S. NeuroStar Advanced Therapy System revenue rose 13% with 34 systems shipped, a 10% increase from prior year

• COST CONTROLS - Operating expenses fell 6% due to savings in general, administrative, sales and marketing costs

Company press release: ID:nGNX84bJRT

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Neuronetics Inc is $3.00, about 48.5% above its May 4 closing price of $2.02

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.